Oxford Nanopore Technologies

Oxford Nanopore Technologies, a UK-based Pharmaceutical Preparation Manufacturing company, has set ambitious climate commitments to significantly reduce its greenhouse gas emissions.

In 2024, Oxford Nanopore Technologies reported Scope 3 emissions of approximately 51,215,000 kg CO2e. Key contributors to these emissions included purchased goods and services at around 36,836,000 kg CO2e, business travel at approximately 5,102,000 kg CO2e, and downstream transportation and distribution at about 1,889,000 kg CO2e. For the previous year, 2023, Scope 3 emissions were approximately 51,814,000 kg CO2e, with purchased goods and services accounting for about 36,477,000 kg CO2e.

Looking further back, in 2022, the company's total emissions from disclosed scopes were approximately 56,606,000 kg CO2e. This included Scope 1 emissions of about 592,000 kg CO2e, Scope 2 emissions (location-based) of around 959,000 kg CO2e, and Scope 3 emissions totalling approximately 54,495,000 kg CO2e. In 2021, the company reported Scope 1 emissions of approximately 393,000 kg CO2e and Scope 2 emissions (location-based) of about 1,178,000 kg CO2e. For 2020, Scope 1 emissions were approximately 359,200 kg CO2e and Scope 2 emissions were around 1,091,700 kg CO2e. Data for Scope 1 and 2 emissions is missing for 2023 and 2024.

Oxford Nanopore Technologies plc has committed to Science Based Targets initiative (SBTi) aligned goals. The company aims for net-zero greenhouse gas emissions across its entire value chain by 2045. As part of its near-term targets, Oxford Nanopore Technologies plc commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2023 base year. Furthermore, the company plans to reduce Scope 3 GHG emissions by 52% per GBP value added within the same timeframe. For its long-term targets, the company is committed to reducing absolute Scope 1, 2, and 3 GHG emissions by 90% by 2045 from a 2023 base year.